ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-PSMA Antibody-drug Conjugate ARX517

Also written as “ARX517” and “JNJ-95298177”.

Its studies are mostly in Prostatic Neoplasms, led by Johnson & Johnson.

Furthest: phase 1, since Sep 12, 20202 company-led studies, 2 open or runningNext primary completion: Dec 31, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson22 open or runningphase 1since Sep 12, 2020Sep 12, 2020Dec 31, 2026phase 1 · NCT04662580
  • Named in Johnson & Johnson’s own pipeline as JNJ-8177 (ARX517), phase 1, as of Oct 13, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 12, 2020First study: phase 1 study in Prostatic NeoplasmsFirst studyNCT04662580 · 183 enrolled · United States
  2. Jul 22, 2025Phase 1 study in Prostatic NeoplasmsNCT07082920 · 140 planned · United States, United Kingdom

Ahead

  1. Dec 31, 2026Primary completion: phase 1 study in Prostatic NeoplasmsNCT04662580
  2. Nov 30, 2027Primary completion: phase 1 study in Prostatic NeoplasmsNCT07082920

TargetBeta

“An antibody-drug conjugate (ADC) containing a humanized immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against prostate-specific membrane antigen (PSMA) and site-specifically conjugated to two of the microtubule-disrupting toxin amberstatin (AS269), with potential antineoplastic act…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) containing a humanized immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against prostate-specific membrane antigen (PSMA) and site-specifically ”NCIt, by rule

Other programs on FOLH1

ProgramCompanyFurthest phaseStudies
flotufolastat F 18ruleBraccophase 47
piflufolastatruleLantheusphase 45
abefolastat tesaroxetan CU-64ruleclarity-pharmaceuticals-ltdphase 35
gallium 68 PSMA-11ruleNovartisphase 34
Lutetium Lu 177 Ludotadipeprulefuturechemphase 33
Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401Johnson & Johnsonphase 32
Lutetium Lu 177 NYM032ruleNorroy Biosciencephase 32
actinium AC-225 vipivotide tetraxetanNovartisphase 32
HRS-4357Jiangsu HengRui Medicinephase 32
zadavotide guraxetanAstraZenecaphase 24
AB-001rulefrontier-biotechnologies-incphase 23
olsutamigruleRegeneron Pharmaceuticalsphase 22

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07082920Prostatic Neoplasms · United States, United Kingdom1RecruitingNov 30, 2027140
NCT04662580Prostatic Neoplasms · United States1Active, not recruitingDec 31, 2026183

How it is read

Names in the registry

  • “ARX517”, 1 entry
  • “JNJ-95298177”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.